Biohit Oyj - Managers' transactions

CORRECTION: Biohit Oyj - Managers' Transactions

Biohit Oyj - Managers' Transactions, February 23, 2017 at 5:30 pm local time
(EET) 

CORRECTION TO BIOHIT OYJ – MANAGER’S TRANSACTIONS IN FEBRUARY 23, 2017 AT 3:50
PM LOCAL TIME (EET) 

Transaction details should read as follows:

Transaction Details

(1): Volume: 13933 Unit price: 3,40920 EUR

(2): Volume: 2776 Unit price: 3,70400 EUR

(3): Volume: 15299 Unit price: 3,51260 EUR

(4): Volume: 3962 Unit price: 3,51260 EUR



Aggregated transactions

(4): Volume: 35970 Volume weighted average price: 3.48732 EUR



The release including the corrected information is found in its entirety

below.





Additional information:
CEO Semi Korpela, Biohit Oyj
tel. +358 9 773 861
investor.relations@biohit.fi
www.biohithealthcare.com



Biohit Oyj - Managers' Transactions

____________________________________________



Person subject to the notification requirement

Name: Korpela, Semi

Position: Chief Executive Officer

Issuer: Biohit Oyj

LEI: 74370089ATTSNBXJVT29



Notification type: INITIAL NOTIFICATION

Reference number: 74370089ATTSNBXJVT29_20170223163749_6

____________________________________________



Transaction date: 2017-02-20

Venue: NASDAQ HELSINKI LTD (XHEL)

Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT

ISIN: FI4000219324

Nature of the transaction: EXERCISE (RIGHTS, PUT AND CALL OPTIONS)

(X) Linked to stock option programme





Transaction Details

(1): Volume: 13933 Unit price: 3,40920 EUR

(2): Volume: 2776 Unit price: 3,70400 EUR

(3): Volume: 15299 Unit price: 3,51260 EUR

(4): Volume: 3962 Unit price: 3,51260 EUR



Aggregated transactions

(4): Volume: 35970 Volume weighted average price: 3.48732 EUR



Additional information:
CEO Semi Korpela, Biohit Oyj
tel. +358 9 773 861
investor.relations@biohit.fi
www.biohithealthcare.com


Biohit in brief

Biohit Oyj is a globally operating Finnish biotechnology company. Biohit’s
mission is “Innovating for Health” – we produce innovative products and
services to promote research and early diagnosis. Biohit is headquartered in
Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit's Series B
share (BIOBV) is quoted on Nasdaq Helsinki in the Small cap/Healthcare group.
www.biohithealthcare.com